Healios K K receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Healios K K (4593)
Healios K K stock price live, this page displays TYO 4593 stock exchange data. View the 4593 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Healios K K real time stock price chart below.
What Is the Healios K K Stock Price Today?
The Healios K K stock price today is 247.0.
What Is the Stock Symbol for Healios K K?
The stock symbol for Healios K K is "4593."
What Stock Exchange Does Healios K K Trade On?
Healios K K is listed and trades on the Tokyo stock exchange.
Is Healios K K a Good Stock to Buy?
Determining whether Healios K K—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 4593 quote. (ISIN: JP3835100003)
What Is the Healios K K Stock Price Today?
The Healios K K stock price today is 247.0.
What Is the Stock Symbol for Healios K K?
The stock symbol for Healios K K is "4593."
What Stock Exchange Does Healios K K Trade On?
Healios K K is listed and trades on the Tokyo stock exchange.
Is Healios K K a Good Stock to Buy?
Determining whether Healios K K—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 4593 quote. (ISIN: JP3835100003)
247.0
+1.0(+0.41%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
243.0
251.0
52 wk Range
208.0
648.0
Earnings results expected in 5 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
243.0251.0
52 wk Range
208.0648.0
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
4593 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
779.8
Upside
+215.72%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Healios K K receives Investment Bank Analyst Rating Update- Investing.com
Pro
Healios K K receives Investment Bank Analyst Rating Update- Investing.com
Pro- Healios K K receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Healios K K receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Healios K K receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Healios K K receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Healios K K receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Healios KK receives Investment Bank Analyst Rating Update- Investing.com
Pro
Healios K K receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy
Analyst Ratings
5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 779.8
(+215.72% Upside)
Earnings
Latest Release
May 14, 2026
EPS / Forecast
-27.65 / -10.98
Revenue / Forecast
8M / 35M
Compare 4593 to Peers and Sector
Metrics to compare | 4593 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4593PeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.6x | −8.8x | −0.4x | |
PEG Ratio | −0.39 | −0.16 | 0.00 | |
Price/Book | 4.4x | 2.7x | 2.6x | |
Price / LTM Sales | 448.8x | 20.5x | 3.0x | |
Upside (Analyst Target) | 204.4% | 118.6% | 50.7% | |
Fair Value Upside | Unlock | 1.8% | 7.2% | Unlock |
Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke; and HLCM051, which is in phase 2 clinical trial for the treatment of trauma, as well as HLCR011, which is in phase 1/2 clinical trial for the treatment of retinal pigmen epithelium and age-related macular degeneration and AKT-01/HLCN061, which is in pre-clinical trial for the treatment of Mesothelioma, Lung cancer, Hepatocellular carcinoma and Gastric cancer(solid tumors). It also develops somatic stem cell and induced pluripotent stem cell regenerative medicines. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Chiyoda, Japan.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Healios K K (4593) Stock Price Today?
The Healios K K stock price today is 247.0 JPY.
What Stock Exchange Does Healios K K Trade On?
Healios K K is listed and trades on the Tokyo Stock Exchange.
What Is the Stock Symbol for Healios K K?
The stock symbol for Healios K K is "4593."
What Is the Healios K K Market Cap?
As of today, Healios K K market cap is 33.35B JPY.
What Is Healios K K's Earnings Per Share (TTM)?
The Healios K K EPS (TTM) is -34.7.
When Is the Next Healios K K Earnings Date?
Healios K K will release its next earnings report on Aug 12, 2026.
From a Technical Analysis Perspective, Is 4593 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Healios K K Stock Split?
Healios K K has split 0 times.
How Many Employees Does Healios K K Have?
Healios K K has 75 employees.
What is the current trading status of Healios K K (4593)?
As of Aug 07, 2026, Healios K K (4593) is trading at a price of 247.0 JPY, with a previous close of 246.0 JPY. The stock has fluctuated within a day range of 243.0 JPY to 251.0 JPY, while its 52-week range spans from 208.0 JPY to 648.0 JPY.
What Is Healios K K (4593) Price Target According to Analysts?
The average 12-month price target for Healios K K is 779.8 JPY, with a high estimate of 1199 JPY and a low estimate of 510 JPY. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +215.72% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.